30results about How to "Inhibition of phagocytosis" patented technology

The invention relates to a method for manufacturing a digital PCR (polymerase chain reaction) chip based on a mineral-oil saturated PDMS (polydimethylsiloxane) material. The method is characterized in that the digital PCR chip based on PDMS is prepared from a PDMS monomer of a certain amount of mineral oil (liquid paraffin) and comprises an emulsion droplet generation structure and an emulsion droplet collection structure. After the emulsion droplets are made and collected on the same chip, the emulsion droplets are subjected to PCR amplification on the same chip. The phagocytosis to the oil phase in the digital PCR system by the PDMS of the chip can be avoided, the emulsion droplets can be kept stable during PCR, and the stability of the PCR can be guaranteed. In addition, compared with the existing technology of the digital PCR chip, the method provided by the invention is low in cost, is convenient to operate and has a very wide application prospect.

The invention relates to a whitening composition and a preparation method as well as application thereof. The whitening composition is prepared from the following components in percentage by mass: 0.01 to 10 percent of oxyresveratrol, 0.01 to 20 percent of radix scutellariae extract, 0.01 to 10 percent of herba thymi mongolici extract, 0.01 to 10 percent of fructus chebulae extract, 0.01 to 15 percent of hydrolyzed prunus domestica, 0.5 to 20 percent of nicotinamide and 0.01 to 10 percent of radix glycyrrhizae glabrae extract. According to the whitening composition disclosed by the invention,a balanced whitening effect can be achieved, i.e., all links of skin whitening can be comprehensively considered, and specifically, all links of melanogenesis incentives (inflammation), a melanogenesis process, a process of blocking transfer of melanin, a process of inhibiting phagocytosis of keratinocyte on the melanin, preventing the melanin from entering the stratum corneum, inhibiting color development and finally digesting and discharging the melanin and the like can be comprehensively considered.

An anticancer Chinese medicine in the form of injection, dripping pill and capsule is prepared from astragalus root, brucea fruit, zedoary oil, coix seed, and optional others. Its preparing process is also disclosed.

The invention relates to the technical field of biological materials and particularly relates to a hyaluronic acid-based postoperative anti-adhesive membrane. The hyaluronic acid-based postoperative anti-adhesive membrane consists of the following components in percentage by weight: 55%-96% of hyaluronic acid, 1%-8% of glycerol, 0%-5% of citric acid, 0.5%-1% of antibiotics and the balance of water. The hyaluronic acid-based postoperative anti-adhesive membrane disclosed by the invention is used for separating an injured tissue from a normal serosa to achieve space-blocking and lubricating effects, and therefore, friction is reduced; bleeding and effusion are inhibited, number of blood blocks forming a permanent adhesion skeleton can be reduced, and fibrous protein deposition is inhibited; postoperative inflammatory cell transfer and phagocytosis are inhibited, and wound healing is promoted; growth and differentiation of serosa mesothelial cells are stimulated, so that the inured serosa achieves physiological repair, and therefore, the hyaluronic acid-based postoperative anti-adhesive membrane has excellent postoperative anti-adhesive effect.

The invention discloses a traditional Chinese medicinal composition for treating infant eczema, acute and chronic eczema, and eczematous dermatitis. The traditional Chinese medicinal composition consists of 20-200 parts of egg oil, 0.5-50 parts of borneol and 0.4-5 parts of shrubby sophora extract. The composition, through a process, can be prepared into clinically acceptable dosage forms, such as an oil agent, an ointment, a gel, a soft capsule, a nano preparation and the like, which are concrete in therapeutic effect and convenient to use, carry and store. Both pharmacological study and clinical research show that the composition has functions of clearing away heat and toxic matters, removing dampness and relieving itch, and the composition is used for treating infant eczema, acute and chronic eczema, and eczematous dermatitis caused by interactive damp and hot; and the composition is free from side effect and capable of promoting aged skin renewal, and has a wide market prospect and social and economic values.

The invention relates to an application of protein in preparation of medicines for preventing and treating atherosclerosis and cardiovascular and cerebrovascular diseases and peripheral vascular diseases related to atherosclerosis. According to the invention, sDSS1 protein is used for preparing the medicines for preventing and treating the diseases. The sDSS1 protein can effectively reduce the level of oxidized low-density lipoprotein in animal blood of an atherosclerosis model, inhibit the ingestion of vascular endothelial cells and macrophages on oxidized low-density lipoprotein, can increase the intake of oxidized low-density lipoprotein by liver cells and reduce the area of atherosclerotic plaques in model group animals, and inhibit the progress of atherosclerosis or the progress of cardiovascular and cerebrovascular diseases and peripheral vascular diseases caused by atherosclerosis, which has great clinical application value.

The present invention relates to a method for producing microalloy ferro-silicon by using a nickle smelting waste slag electric stove integral deoxidation and reduction, including the steps as follows: a. obtaining a ferro-silicon of a high-temperature molten state by deoxidation and reduction of the nickle smelting waste slag as an iron raw material and other raw material; b. pouring the ferro-silicon into a foundry ladle to insulate to ensure the ferro-silicon to be in the molten state, at the same time infusing chlorine gas into the ferro-silicon to generate solid residue to purify; c. removing the solid residue. For the method of the invention, the nickel smelting waste slag is directly used to replace the iron raw material such as steel shaving, iron scale, sintered ball cluster and the like for the ferro-silicon production, thus it is capable of reducing the dosage of dinas rock or rock quartz; it has been found that the ferro-silicon (FeSi75) produced by the method meets the national standard completely; the invention provides a novel method for producing ferroalloy.

The invention discloses application of intestinal alkaline phosphatase as a human neutrophile granulocyte removal inhibitor, a human mononuclear cell removal inhibitor, a humanneutrophile granulocytephagocytosis inhibitor and a mononuclear cell apoptosis accelerant in the presence or absence of endotoxin, and application of the intestinal alkaline phosphatase as a reversion preparation for treating diseases that human neutrophile granulocyte apoptosis is inhibited by the endotoxin. The invention further discloses application of the intestinal alkaline phosphatase in preparing medicines for treating related diseases and in treatment on related diseases. The invention further discloses a product activity quality control method of an industrial or commercial alkaline phosphatase preparation.The application disclosed by the invention is independent from known anti-inflammation mechanisms and application that the endotoxin is inactivated by the intestinal alkaline phosphatase to inhibit secretion of human leukocyte TNF-alpha and IL-6, and application of the alkaline phosphatase is greatly widened.

The invention discloses a baby eczema lotion and a preparation method thereof. The lotion comprises the components of, by weight: 50-100 parts of redroot gromwell, 45-90 parts of light-yellow sophora root, 30-100 parts of Taiwan angelica root, and 60-120 parts of fragrant solomonseal rhizome. According to the invention, on a basis of heat clearing and dampness eliminating of traditional baby eczema treatment, a blood-cooling and detoxifying method is adopted. Also, considering the characteristics of baby skins, blood-cooling detoxifying, wind-evil-dispelling, dampness-eliminating, heat-clearing, itching-relieving, and skin-moisturizing traditional Chinese medicines are adopted for preparing the lotion, such that baby skins can be moisturized when baby eczema is cured. No significant side effect is found currently. The invention also discloses a preparation method of the baby eczema lotion.

The invention discloses an anti-infection unguent with traditional Chinese medicine and probiotics. The unguent is prepared from medical vaseline, glucose, pearl powder, trehalose, sanguisorba officinalis, myrrh, boswellia carterii, radix notoginseng, radix aconiti brachypodi, borneol and the like. The traditional Chinese medicine is combined with the probiotics, so that the utilization rate of the traditional Chinese medicine is effectively increased. According to the traditional Chinese medicine theory, skin is nursed, the immunity and resistance of the skin are improved, and accordingly theresistance of the skin to germs and the adaptability of the skin to the external environment are improved. The traditional Chinese medicine is combined with the probiotics, and metabolism of the skinis improved. According to the anti-infection unguent with the traditional Chinese medicine and probiotics, the growth of pathogenic bacteria is inhibited, the pathogenic bacteria are devoured, accordingly infection is avoided, and tissue regeneration is conducted by using the traditional Chinese medicine. The anti-infection unguent with the traditional Chinese medicine and probiotics has remarkable effects of sterilization and anti-inflammation and the remarkable effects of clearing heat, removing toxicity and relieving pain and has the advantages of being short in treatment course, capable of taking effect quickly, good in curative effect and the like, relapse cannot happen after rehabilitation, no sequela exists, and a scar is not easily left.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to an isoliquiritigenin nanosuspension and a preparation method and application thereof. The isoliquiritigenin nanosuspension is composed of isoliquiritigenin and a space stabilizer with a mass ratio of 1:(0.1-10), wherein the particle size is 200-700 nm, and the electric potential is -30 mV to 20 mV. The space stabilizer is one or more of hydroxypropyl cellulose, povidone K30, hydroxypropyl methyl cellulose, polyethylene glycol 6000, vitamin E polyethylene glycol succinate and croscarmellose sodium. The isoliquiritigenin nanosuspension is high in drug loading capacity and good in stability, and the cumulative dissolution rate and dissolution rate are also remarkably increased. In-vitro cell experiments show that: compared with an isoliquiritigenin raw material medicine, the capacity of inducing lung cancer A549 cell apoptosis is remarkably improved, the capacities of being taken in by tumor cells and inhibiting cancer cell proliferation are also remarkably enhanced, and a new thought is provided for improving the solubility and anti-tumor activity of indissolvable medicines.

The invention discloses an immune cell therapeutic agent for atherosclerotic plaque as well as a preparation method and application of the immune cell therapeutic agent. Relates to the technical field of cell engineering. According to the immune cell therapeutic agent for atherosclerotic plaque, mononuclear macrophages are taken as a basis, a system CD47p-GQDs-miRNA223 formed by crosslinking a membrane modification material CD47p, a nano auxiliary intermediate vector GQDs and a gene drug miRNA223 is taken as a tool, and the M-CD47p-GQDs-miRNA223 is constructed by utilizing a cell surface nano engineering technology. The immune cell therapeutic agent disclosed by the invention can be used for precisely delivering the medicine to an AS focus in a targeting manner, so that the problem that the treatment effect obtained by whole-body non-specific distribution of the medicine in AS non-invasive treatment is not remarkable is solved.

The invention relates to a polypeptide, a polypeptide-modified lipid carrier and application of the lipid carrier as a medicament for inhibiting phagocytosis of macrophages. The invention provides a method capable of enabling the lipid carrier to be adhered to the surface of macrophage cell membrane for a long time so as to promote the delivery of nanoparticles in vivo based on the fact that a nano preparation is easy to be phagocytosed and metabolized by macrophages during the in-vivo delivery. After "Self" D-type polypeptide and phospholipid or other materials form a lipid carrier, when thelipid carrier reacts with the macrophages, the lipid carrier can stay on the surface of the macrophages for a long time so as to inhibit the phagocytosis of the macrophages and to improve the in-vivodelivery of the nano carrier remarkably. The lipid carrier of the invention can be adhered to the surface of the macrophage, promote the phosphorylation of SIRP alpha protein of the macrophages, and inhibit the phagocytosis of the macrophages. After entering the body, the carrier can inhibit phagocytosis of the macrophages and prolong the in-vivo half-life of a subsequently-injected medicament. The research of the invention shows that by administering the lipid carrier, the half-life of the nano preparation in vivo can be obviously prolonged, and the distribution of medicament in liver and spleen can be reduced.

The invention discloses a construction method of a peak camel source phage display nano antibody, which comprises the following steps: based on a phage display technology, preparing an antibody by utilizing peak camel immunization, preparing the antibody, loading the antibody to a phage display carrier, and screening the prepared antibody by utilizing the characteristic that a specific antibody can be obtained by screening by utilizing a phage display antibody library, so as to obtain the peak camel source phage display nano antibody. The hCD47nb nano antibody with good binding capacity aiming at CD47 is obtained, the prepared hCD47nb can effectively promote the phagocytic ability of macrophages to cancerous cells, inhibition of the CD47 to the phagocytic effect of the macrophages is avoided, meanwhile, the prepared hCD47nb nano antibody is basically not combined with human red blood cells, aggregation of the red blood cells cannot be caused, the influence on the human body is small, and the hCD47nb nano antibody has good application prospects. Therefore, the cable has excellent use performance and market prospect.